<DOC>
	<DOCNO>NCT01585285</DOCNO>
	<brief_summary>The purpose AMI-PONT trial ass whether result term graft patency novel coronary artery bypass ( CABG ) strategy , include saphenous vein bridge distribute arterial flow leave anterior mammary artery ( LIMA ) anterolateral territory , inferior conventional CABG strategy combine separate LIMA graft leave anterior descend coronary vein graft target vessel anterolateral territory .</brief_summary>
	<brief_title>Coronary Artery Bypass Grafting Strategies Anterolateral Territory : Prospective Randomized Clinical Trial</brief_title>
	<detailed_description>Purpose : This novel surgical design use composite-sequential venous graft distribute leave anterior mammary artery ( LIMA ) inflow directly leave anterior descend coronary ( LAD ) , also branch anterolateral territory thereby promote high flow LIMA pedicle . It construct use short saphenous vein graft ( SVG ) bridge ( LSVB ) interpose LAD one ( ) anterolateral target , LIMA graft hood SVG LAD anastomosis . Objectives . The main objective prospective randomize clinical trial AMI-PONT ass whether CABG strategy include LSVB distribute LIMA outflow provide non-inferior patency rate compare conventional CABG surgery separate LIMA graft LAD SVG anterolateral target . Methods . Two hundred adult patient undergoing primary isolated CABG , require graft LAD least one anterolateral target , randomize 1:1 two treatment arm : 1 ) CABG strategy LSVB ; 2 ) conventional CABG strategy LIMA graft LAD separate aorto-coronary SVG anterolateral target . Patients assess clinically 30 day , 6 month , one , five ten year . They undergo graft patency assessment one five year use Multi-Slice Computed Tomography . All patient undergo CABG use cardiopulmonary bypass ( CPB ) . Patients exclude contraindication CPB MSCT graft assessment .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients undergo coronary artery bypass grafting ( CABG ) surgery ( single , double triple vessel disease ) eligible : 1. require isolate CABG median sternotomy least one leave anterior descending ( LAD ) site another anterolateral target ; 2. provide write informed consent ; 3. 21 year age . A patient exclude study he/she fulfill inclusion criterion , patient treat physician refuse study follow observe : 1. concomitant cardiac procedure associate CABG include valve surgery ascend aorta surgery ; 2. contraindication cardiopulmonary bypass ( calcified aorta ) ; 3. unusable leave internal mammary artery ( LIMA ) uncorrected subclavian artery stenosis , anterior chest trauma , radiation injury harvest preclude use LIMA ; 4. concomitant lifethreatening disease likely limit life expectancy le 2 year ; 5. emergency CABG surgery ( immediate revascularization hemodynamic instability preclude patient consent ) ; 6. prior CABG ; 7. severe congestive heart failure leave ventricular ejection fraction le 30 % . Other exclusion criterion preclude MSCT include : 8. moderate severe renal impairment ( estimate glomerular filtration rate , eGFR &lt; 50 mL/min/1.73 m2 ) ; 9. chronic atrial fibrillation ( preclude ECGgating MSCT ) ; 10. history severe hypersensitivity iodinate contrast agent ; 11. know suspected pheochromocytoma ; 12. pregnant/lactating female . Furthermore , patient may exclude time MSCT : 13. persistent rapid ( &gt; 100/min ) atrial fibrillation cardiac rhythm precludes reliable ECG triggering ; 14. severe congestive heart failure , New York Heart Association ( NYHA ) Class IV , despite coronary revascularization maximal medical treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Coronary artery bypass grafting</keyword>
	<keyword>Left internal mammary artery</keyword>
	<keyword>Composite grafting</keyword>
	<keyword>Multislice Spiral Computed Tomography Scanner</keyword>
	<keyword>Graft patency assessment</keyword>
</DOC>